Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: A randomised trial

The Lancet

Volumn 379, Issue 9819, 2012, Pages 923-931

  Thiele, Holger ^a   Wöhrle, Jochen ^b   Hambrecht, Rainer ^c   Rittger, Harald ^d   Birkemeyer, Ralf ^e   Lauer, Bernward ^f   Neuhaus, Petra ^a   Brosteanu, Oana ^a   Sick, Peter ^g   Wiemer, Marcus ^h   Kerber, Sebastian ⁱ   Kleinertz, Klaus ^j   Eitel, Ingo ^a   Desch, Steffen ^a   Schuler, Gerhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Klinikum Links der Weser   (Germany)

^d KLINIKUM COBURG   (Germany)

^e SCHWARZWALD BAAR KLINIKUM   (Germany)

^f ZENTRALKLINIK BAD BERKA   (Germany)

^g Krankenhaus der Barmherzigen Bruder   (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ Department of Cardiology   (Germany)

^j Ambulantes Herzzentrum Chemnitz   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PRASUGREL;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BOLUS INJECTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART REINFARCTION; HUMAN; INTRACORONARY INFUSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84858072051     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61872-2     Document Type: Article

References (30)

1. F Van de Werf, J Bax, A Betriu et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
2. G Niccoli, F Burzotta, L Galiuto, F Crea Myocardial no-reflow in humans J Am Coll Cardiol 54 2009 281 292
3. G De Luca, E Navarese, P Marino Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials Eur Heart J 30 2009 2705 2713
4. FJ Neumann, R Blasini, C Schmitt et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction Circulation 98 1998 2695 2701 (Pubitemid 28564004)
5. AJ Deibele, LK Jennings, JE Tcheng, C Neva, AD Earhart, CM Gibson Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) trial Circulation 121 2010 784 791
6. YL Gu, MA Kampinga, WG Wieringa et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) Trial Circulation 122 2010 2709 2717
7. H Thiele, K Schindler, J Friedenberger et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IS in ST-elevation myocardial infarction trial Circulation 118 2008 49 57
8. S Desch, A Siegemund, U Scholz et al. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-segment elevation myocardial infarction Clin Res Cardiol 101 2011 117 124
9. F Bellandi, M Maioli, M Gallopin, A Toso, RP Dabizzi Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention Catheter Cardiovasc Interv 62 2004 186 192 (Pubitemid 38788695)
10. EP Navarese, M Kozinski, K Obonska et al. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials Platelets 2011 10.3109/09537104.2011.619602 published online Oct 11.
11. H Thiele, J Wöhrle, P Neuhaus et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial Am Heart J 159 2010 547 554
12. SJ Pocock Current issues in the design and interpretation of clinical trials BMJ (Clin Res Ed) 290 1985 39 42 (Pubitemid 15075985)
13. R Schröder Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction Circulation 110 2004 e506 e510
14. OF Bertrand, J Rodes-Cabau, E Larose et al. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study Am J Cardiol 105 2010 1520 1527
15. A Dominguez-Rodriguez, P Abreu-Gonzalez, P Avanzas et al. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention - effects on soluble CD40 ligand concentrations Atherosclerosis 206 2009 523 527
16. A Iversen, U Abildgaard, A Galloe et al. Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial J Interv Cardiol 24 2011 105 111
17. A Dechartres, I Boutron, L Trinquart, P Charles, P Ravaud Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study Ann Intern Med 155 2011 39 51
18. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial Lancet 367 2006 569 578
19. EC Keeley, JA Boura, CL Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20 (Pubitemid 36050955)
20. CM Gibson, A Maehara, AJ Lansky et al. Rationale and design of the INFUSE-AMI study: a 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction Am Heart J 161 2011 478 486
21. SJ Marciniak Jr, MA Mascelli, MI Furman et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates Thromb Haemost 87 2002 1020 1025 (Pubitemid 34624885)
22. MA Mascelli, ET Lance, L Damaraju, CL Wagner, HF Weisman, RE Jordan Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade Circulation 97 1998 1680 1688 (Pubitemid 28211416)
23. J Mehilli, A Kastrati, S Schulz et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial Circulation 119 2009 1933 1940
24. AWJ van't Hof, J ten Berg, T Heestermans et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 372 2008 537 546
25. SD Wiviott, E Braunwald, CH McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
26. KA Fox, K Carruthers, PG Steg et al. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events Eur Heart J 31 2010 667 675
27. MT Roe, JC Messenger, WS Weintraub et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention J Am Coll Cardiol 56 2010 254 263
28. GW Stone, B Witzenbichler, G Guagliumi et al. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230 (Pubitemid 351724451)
29. The TIMI Study Group Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial N Engl J Med 320 1989 618 627
30. S Sadandan Results of CRYSTAL AMI http://www.clinicaltrialresults.org (accessed Nov 26, 2011).